These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. J Clin Psychiatry; 2008 Feb; 69(2):302-9. PubMed ID: 18211129 [Abstract] [Full Text] [Related]
8. Quetiapine: a review of its use in the management of bipolar depression. Sanford M, Keating GM. CNS Drugs; 2012 May 01; 26(5):435-60. PubMed ID: 22519923 [Abstract] [Full Text] [Related]
9. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. Derry S, Moore RA. BMC Psychiatry; 2007 Aug 16; 7():40. PubMed ID: 17705840 [Abstract] [Full Text] [Related]
10. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. Maneeton N, Maneeton B, Srisurapanont M, Martin SD. BMC Psychiatry; 2012 Sep 27; 12():160. PubMed ID: 23017200 [Abstract] [Full Text] [Related]
16. Typical and atypical antipsychotics in bipolar depression. Gao K, Gajwani P, Elhaj O, Calabrese JR. J Clin Psychiatry; 2005 Nov 27; 66(11):1376-85. PubMed ID: 16420074 [Abstract] [Full Text] [Related]
17. Antipsychotics for fibromyalgia in adults. Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W. Cochrane Database Syst Rev; 2016 Jun 02; 2016(6):CD011804. PubMed ID: 27251337 [Abstract] [Full Text] [Related]
18. A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use. Gao K, Ganocy SJ, Conroy C, Brownrigg B, Serrano MB, Calabrese JR. Psychopharmacology (Berl); 2017 Aug 02; 234(15):2233-2244. PubMed ID: 28536866 [Abstract] [Full Text] [Related]
19. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Kishi T, Yoshimura R, Sakuma K, Okuya M, Iwata N. Neuropsychopharmacol Rep; 2020 Dec 02; 40(4):417-422. PubMed ID: 32902200 [Abstract] [Full Text] [Related]